Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 7, 2007; 13(21): 2945-2951
Published online Jun 7, 2007. doi: 10.3748/wjg.v13.i21.2945
Published online Jun 7, 2007. doi: 10.3748/wjg.v13.i21.2945
Table 3 Median survival time in different cancers
| CRR median months(95% CI) | RO median months(95% CI) | |
| All cancers | 30.2 (25.5, 34.9) | 35.9 (10.5, 61.3) |
| LNN negative | 30.2 (17.9, 42.4) | 37.4 (7.8, 6.7) |
| LNN positive | 27.0 (0, 55.2) | 20.7 (16.7, 34.6) |
| Ductal adenocancers | 27.0 (5.5, 48.4) | 20.2 (0, 52.0) |
| LNN negative | 30.0 (9.9, 50.5) | 20.2 (19.6, 20.3) |
| LNN positive | 27.0 (0, 55.2) | 39.0 (0, 110.5) |
| Ampullar cancers | 39.4 (5.9, 72.8) | |
| Cystadenocancers | 20.7 (00, 48.2) | |
- Citation: Vento P, Mustonen H, Joensuu T, Kärkkäinen P, Kivilaakso E, Kiviluoto T. Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer. World J Gastroenterol 2007; 13(21): 2945-2951
- URL: https://www.wjgnet.com/1007-9327/full/v13/i21/2945.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i21.2945